Jeffrey Meyer, DO
Psychiatry · Kansas City, MONPI 1962559377
Payments from drug & device makers
Across 252 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$639
- Johnson & Johnson$627
- AbbVie$539
- Otsuka America Pharmaceutical, Inc.$399
- Teva Pharmaceuticals USA, Inc.$352
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$246
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,306100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 25 | $639 |
| Johnson & Johnson | 23 | $627 |
| AbbVie(2 entities) | 31 | $539 |
| Otsuka America Pharmaceutical, Inc. | 23 | $399 |
| Teva Pharmaceuticals USA, Inc. | 15 | $352 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $246 |
| Indivior Inc. | 11 | $236 |
| Axsome Therapeutics, Inc. | 11 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $201 |
| Vanda Pharmaceuticals Inc. | 8 | $196 |
| Corium, LLC | 6 | $157 |
| Neurocrine Biosciences, Inc. | 7 | $145 |
| Supernus Pharmaceuticals, Inc. | 7 | $129 |
| Noven Therapeutics, LLC | 7 | $121 |
| Lundbeck LLC | 5 | $113 |
| E.r. Squibb & Sons, L.L.C. | 1 | $106 |
| Merck | 7 | $100 |
| Harmony Biosciences LLC | 3 | $78 |
| Ironshore Pharmaceuticals Inc. | 3 | $78 |
| Braeburn Inc. | 3 | $75 |
| Jazz Pharmaceuticals Inc. | 4 | $73 |
| Shire North American Group Inc | 4 | $68 |
| Bausch Health US, LLC | 3 | $57 |
| Orexo US, Inc. | 3 | $49 |
| Adlon Therapeutics L.p. | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 3 | $41 |
| Alfasigma USA, Inc. | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $27 |
| Vertical Pharmaceuticals, LLC | 2 | $25 |
| Biogen | 1 | $25 |
| Almatica Pharma LLC | 1 | $21 |
| Tris Pharma Inc | 1 | $20 |
| Neos Therapeutics, LP | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,332 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 65 | $78,454 |
| Invega SustennaPaliperidone Palmitate | 11 | $37,371 |
| RexultiBrexpiprazole | 17 | $32,589 |
| VraylarCariprazine Hcl | 26 | $31,033 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 174 | $21,139 |
| Aripiprazole | 158 | $15,049 |
| TrintellixVortioxetine Hydrobromide | 13 | $10,800 |
| Lurasidone Hcl | 44 | $9,301 |
| Bupropion XlBupropion Hcl | 198 | $5,699 |
| Duloxetine Hcl | 227 | $5,470 |
| Quetiapine Fumarate | 192 | $5,428 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 118 | $3,778 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 14 | $2,801 |
| Divalproex Sodium ErDivalproex Sodium | 21 | $2,449 |
| Vilazodone Hcl | 28 | $2,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $627 | $115,82576 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $399 | $32,58917 claims |
| AbbVieVraylar | $539 | $31,03326 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $201 | $10,80013 claims |
| Almatica Pharma LLCSertraline Hcl | $21 | $1,04085 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Kansas City
- Brian BarashKansas City$857K
- Mark CannonKansas City$19K
- Syed KarimKansas City$17K
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.